Regeneron Pharmaceuticals, Inc. (REGN)
Regeneron Pharmaceuticals, Inc. (REGN) is a healthcare company (biotechnology) based in the United States. The share price is $957.90, up 0.58% on the day, which values the company at $99.09B. Price as of 17 Nov 2026, 19:10 UTC, from Yahoo Finance.
Key facts
- Share price
- $957.90+0.58% today
- Market value
- $99.09B
- P/E ratio
- 21.2×last 12 months
- Forward P/E
- 13.5×
- Dividend yield
- 0.39%
- Funk Score
- 68/100
- Against its own history
- About its usual priceusual price $1,012.11
- 200-week average
- $783.9122% above
Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.
Regeneron Pharmaceuticals, Inc. in more detail
REGN trades at 21.2× its last twelve months' earnings, 13.5× next year's expected earnings, 5.9× sales. Measured against its own history, the price is 5% below what its usual multiples would imply ($1,012.11) — about its usual price. It sits 22% above its 200-week average of $783.91.
Over the last five fiscal years Regeneron Pharmaceuticals, Inc. has compounded revenue 11.0% a year, earnings per share 6.3% a year, free cash flow 13.4% a year. Its Funk Score is 68 out of 100 (financial strength 9.1, profitability 6.6, growth 5.6, value 6.1, each out of 10).
In its favour: Altman Z in the safe zone; More cash than debt. Worth checking: Gross margin is shrinking.
10 of the superinvestors tracked here hold REGN, including Mason Hawkins (5.0% of the portfolio), Harry Burn (3.0% of the portfolio), Dodge & Cox team (1.9% of the portfolio).
Superinvestors holding REGN
10 of the investors tracked here report a position in their latest 13F filing.
- Mason Hawkins Southeastern Asset Management (Longleaf)4.95% of portfolio · $95M · added · Q2 2026
- Harry Burn Sound Shore Management2.99% of portfolio · $95.7M · trimmed · Q3 2026
- Dodge & Cox team Dodge & Cox1.94% of portfolio · $3.6B · trimmed · Q3 2026
- John Overdeck and David Siegel (founders) Two Sigma Investments0.48% of portfolio · $659.3M · added · Q3 2026
- Josef Lakonishok LSV Asset Management0.35% of portfolio · $186.6M · trimmed · Q3 2026
- Jim Simons (1938–2024) Renaissance Technologies0.28% of portfolio · $206.4M · added · Q3 2026
- Cliff Asness AQR Capital Management0.25% of portfolio · $702.2M · trimmed · Q2 2026
- Joel Greenblatt Gotham Asset Management0.15% of portfolio · $65.6M · added · Q2 2026
- Ray Dalio (founder) Bridgewater Associates0.13% of portfolio · $32M · added · Q2 2026
- Jeremy Grantham (co-founder) GMO (Grantham, Mayo, Van Otterloo)0.12% of portfolio · $53.9M · trimmed · Q3 2026
Health Care companies of similar size
- Vertex PharmaceuticalsVRTX
- MedtronicMDT
- Bristol-Myers SquibbBMY
- StrykerSYK
- McKessonMCK
- SanofiSNY
- ModernaMRNA
- CVS HealthCVS
- HCA HealthcareHCA
- GSKGSK
- Elevance HealthELV
- Cigna GroupCI
Side by side:REGN vs ELV (Regeneron Pharmaceuticals, Inc. vs Elevance Health)REGN vs GSK (Regeneron Pharmaceuticals, Inc. vs GSK)REGN vs HCA (Regeneron Pharmaceuticals, Inc. vs HCA Healthcare)REGN vs CVS (Regeneron Pharmaceuticals, Inc. vs CVS Health)REGN vs MRNA (Regeneron Pharmaceuticals, Inc. vs Moderna)
All health care companies by market valueLargest companies in the United StatesAll stocks A–Z
Regeneron Pharmaceuticals, Inc. (REGN): questions and answers
What is REGN's P/E ratio?
Regeneron Pharmaceuticals, Inc. trades at 21.2× its last twelve months' earnings and 13.5× next year's expected earnings. At its fiscal year-ends over the past 14 years the P/E ranged from 8.8× to 137.7×, with a median of 22.8×.
What is REGN's PEG ratio?
Regeneron Pharmaceuticals, Inc.'s PEG ratio is 1.16 — its P/E divided by its expected earnings growth. Around 1 is the classic sign of a price that matches the growth; well above it means the growth is being paid for in advance.
What is Regeneron Pharmaceuticals, Inc.'s market cap?
Regeneron Pharmaceuticals, Inc. is valued at $99.09B at a share price of $957.90.
Is REGN overvalued or undervalued?
Against its own history, REGN is about its usual price: the price is 5% below the $1,012.11 implied by the median multiples it has traded at (price / earnings, price / sales, price / book, price / free cash flow). That compares the stock with its past; it does not say whether the business now deserves a higher or lower multiple.
Is REGN above its 200-week moving average?
Yes. REGN is 22.2% above its 200-week average of $783.91. Long-term investors watch that line because strong companies rarely trade below it for long.
How fast is Regeneron Pharmaceuticals, Inc. growing?
Over the last five fiscal years Regeneron Pharmaceuticals, Inc.'s revenue grew 11.0% a year and its earnings per share 6.3% a year; over ten years revenue grew 13.3% a year.
Learn to read these numbers
All stocks guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
- Free cash flow and FCF yield explained
Free cash flow is the cash a business generates from operations minus what it spends on equipment, buildings and other long-lived assets. Free-cash-flow yield divides that cash by the company's market value: $5 billion of free cash flow on a $100 billion company is a 5% yield. It is cash available to owners and lenders, not profit.
Cite this page
Funkfolio, “Regeneron Pharmaceuticals, Inc. (REGN) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/REGN
Underlying data: Yahoo Finance; company filings with the SEC.